Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer.
Schoenfeld AJ, Chan JM, Kubota D, Sato H, Rizvi H, Daneshbod Y, Chang JC, Paik PK, Offin M, Arcila ME, Davare MA, Shinde U, Pe'er D, Rekhtman N, Kris MG, Somwar R, Riely GJ, Ladanyi M, Yu HA. Schoenfeld AJ, et al. Among authors: davare ma. Clin Cancer Res. 2020 Jun 1;26(11):2654-2663. doi: 10.1158/1078-0432.CCR-19-3563. Epub 2020 Jan 7. Clin Cancer Res. 2020. PMID: 31911548 Free PMC article.
Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins.
Davare MA, Saborowski A, Eide CA, Tognon C, Smith RL, Elferich J, Agarwal A, Tyner JW, Shinde UP, Lowe SW, Druker BJ. Davare MA, et al. Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19519-24. doi: 10.1073/pnas.1319583110. Epub 2013 Nov 11. Proc Natl Acad Sci U S A. 2013. PMID: 24218589 Free PMC article.
A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer.
Drilon A, Somwar R, Wagner JP, Vellore NA, Eide CA, Zabriskie MS, Arcila ME, Hechtman JF, Wang L, Smith RS, Kris MG, Riely GJ, Druker BJ, O'Hare T, Ladanyi M, Davare MA. Drilon A, et al. Among authors: davare ma. Clin Cancer Res. 2016 May 15;22(10):2351-8. doi: 10.1158/1078-0432.CCR-15-2013. Epub 2015 Dec 16. Clin Cancer Res. 2016. PMID: 26673800 Free PMC article.
Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes.
Hosseini MM, Kurtz SE, Abdelhamed S, Mahmood S, Davare MA, Kaempf A, Elferich J, McDermott JE, Liu T, Payne SH, Shinde U, Rodland KD, Mori M, Druker BJ, Singer JW, Agarwal A. Hosseini MM, et al. Among authors: davare ma. Leukemia. 2018 Nov;32(11):2374-2387. doi: 10.1038/s41375-018-0112-2. Epub 2018 Mar 29. Leukemia. 2018. PMID: 29743719 Free PMC article.
A blast from the past: ROS1 on the brain.
Odintsov I, Somwar R, Davare MA. Odintsov I, et al. Among authors: davare ma. Oncotarget. 2019 Mar 1;10(18):1664-1666. doi: 10.18632/oncotarget.26752. eCollection 2019 Mar 1. Oncotarget. 2019. PMID: 30899438 Free PMC article. No abstract available.
MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions.
Sato H, Schoenfeld AJ, Siau E, Lu YC, Tai H, Suzawa K, Kubota D, Lui AJW, Qeriqi B, Mattar M, Offin M, Sakaguchi M, Toyooka S, Drilon A, Rosen NX, Kris MG, Solit D, De Stanchina E, Davare MA, Riely GJ, Ladanyi M, Somwar R. Sato H, et al. Among authors: davare ma. Clin Cancer Res. 2020 Jun 15;26(12):2932-2945. doi: 10.1158/1078-0432.CCR-19-3321. Epub 2020 Mar 2. Clin Cancer Res. 2020. PMID: 32122926 Free PMC article.
71 results